TRAIL: at the center of drugable anti-tumor pathways

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• The Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway is recognized for its role in cellular anti-cancer networks.
• Recent studies highlight TRAIL's involvement in the selective apoptosis of Acute Myeloid Leukemia (AML) cells when treated with histone deacetylase inhibitors (HDACi).

Purpose of the Study:

• To summarize findings on the role of the TRAIL pathway in the apoptotic mechanisms of HDAC inhibitors and retinoids in cancer therapy.

Main Methods:

• In vivo and in vitro molecular analyses.
• Review and summarization of existing research findings.

Main Results:

• The TRAIL pathway is a critical mediator of apoptosis induced by HDAC inhibitors in cancer cells.
• TRAIL pathway activation is also implicated in the anti-cancer effects of retinoids and their combinations.

Conclusions:

• The TRAIL pathway is a key determinant of therapeutic efficacy for HDAC inhibitors and retinoids in treating cancers like AML.
• Targeting the TRAIL pathway could enhance the effectiveness of these anti-cancer agents.